Incyte Genomics Inc
INCY Real Time Price USDRecent trades of INCY by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in INCY holdings by institutional investors
Quarterly net insider trading by INCY's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$530,000 Jan 20, 2026 Issue: Medicare/Medicaid
-
$330,000 Oct 20, 2025 Issue: Medicare/Medicaid
-
$520,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$240,000 Apr 21, 2025 Issue: Medicare/Medicaid
-
$350,000 Feb 21, 2025 Issue: Medicare/Medicaid
-
$220,000 Oct 21, 2024 Issue: Medicare/Medicaid
-
$300,000 Jul 22, 2024 Issue: Medicare/Medicaid
-
$460,000 Apr 22, 2024 Issue: Medicare/Medicaid
-
$360,000 Oct 20, 2023 Issue: Medicare/Medicaid
-
$220,000 Jul 20, 2023 Issue: Medicare/Medicaid
-
$180,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$220,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid
-
$200,000 Jul 21, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
-
$280,000 Apr 20, 2022 Issue: Medicare/Medicaid
-
$110,000 Jan 21, 2022 Issue: MEDICARE/MEDICAID
-
$190,000 Oct 20, 2021 Issue: MEDICARE/MEDICAID
-
$500,000 Jul 20, 2021 Issue: MEDICARE/MEDICAID
-
$200,000 Apr 20, 2021 Issue: MEDICARE/MEDICAID
-
$50,000 Jan 21, 2021 Issue: Health Issues
-
$50,000 Jan 20, 2021 Issue: None
-
$20,000 Jan 19, 2021 Issue: None
-
$50,000 Oct 20, 2020 Issue: Health Issues
-
$50,000 Oct 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Jul 20, 2020 Issue: Medicare/Medicaid
-
$50,000 Apr 27, 2020 Issue: MEDICARE/MEDICAID
-
$50,000 Apr 17, 2020 Issue: Medicare/Medicaid
-
$30,000 Jan 21, 2020 Issue: MEDICARE/MEDICAID
-
$30,000 Jan 18, 2020 Issue: Medicare/Medicaid
-
$20,000 Mar 26, 2003 Issue: Copyright/Patent/Trademark
-
$20,000 Aug 22, 2002 Issue: Copyright/Patent/Trademark
-
$20,000 Mar 14, 2002 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 20, 2002 Issue: None
-
$20,000 Sep 28, 2001 Issue: Copyright/Patent/Trademark
-
$60,000 Feb 15, 2000 Issue: Medical/Disease Research/Clinical Labs
-
$40,000 Aug 16, 1999 Issue: Medical/Disease Research/Clinical Labs
INCY Estimated quarterly lobbying spending
INCY Revenue by Segment or Geography
New INCY patent grants
-
Patent Title: Processes for preparing jak inhibitors and related intermediate compounds Apr. 07, 2015
-
Patent Title: 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Mar. 31, 2015
-
Patent Title: Processes for preparing jak inhibitors and related intermediate compounds Mar. 31, 2015
-
Patent Title: Processes and intermediates for making a jak inhibitor Mar. 24, 2015
-
Patent Title: N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase Feb. 10, 2015
-
Patent Title: Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Feb. 03, 2015
-
Patent Title: Pyrimidinones as pi3k inhibitors Jan. 27, 2015
-
Patent Title: Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Jan. 13, 2015
-
Patent Title: Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors Jan. 13, 2015
-
Patent Title: Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same Dec. 02, 2014
-
Patent Title: Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors Nov. 25, 2014
-
Patent Title: Antibody to secreted polypeptide Nov. 18, 2014
-
Patent Title: Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Nov. 18, 2014
-
Patent Title: Processes for preparing jak inhibitors and related intermediate compounds Nov. 11, 2014
-
Patent Title: Macrocyclic compounds and their use as kinase inhibitors Oct. 28, 2014
-
Patent Title: Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Oct. 07, 2014
-
Patent Title: Modulators of indoleamine 2,3-dioxygenase and methods of using the same Sep. 30, 2014
-
Patent Title: Substituted heterocycles as janus kinase inhibitors Sep. 23, 2014
-
Patent Title: Azepine inhibitors of janus kinases Sep. 16, 2014
-
Patent Title: Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Sep. 09, 2014
-
Patent Title: 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Sep. 02, 2014
-
Patent Title: Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Sep. 02, 2014
-
Patent Title: 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Aug. 05, 2014
-
Patent Title: Antibodies to human β-adrenergic receptor kinase Jul. 15, 2014
-
Patent Title: Piperidin-4-yl azetidine derivatives as jak1 inhibitors Jul. 01, 2014
-
Patent Title: Macrocyclic compounds and their use as kinase inhibitors Jul. 01, 2014
-
Patent Title: Substituted heteroaryl fused derivatives as pi3k inhibitors Jun. 24, 2014
-
Patent Title: Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 Jun. 17, 2014
-
Patent Title: Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun. 10, 2014
-
Patent Title: Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors Jun. 03, 2014
-
Patent Title: 3-aminopyrrolidine derivatives as modulators of chemokine receptors May. 20, 2014
-
Patent Title: Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile May. 13, 2014
-
Patent Title: Compositions comprising signal peptide-containing proteins May. 06, 2014
-
Patent Title: N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors May. 06, 2014
-
Patent Title: Purinone derivatives as hm74a agonists Apr. 22, 2014
-
Patent Title: 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors Apr. 15, 2014
-
Patent Title: Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors Apr. 08, 2014
-
Patent Title: Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors Mar. 25, 2014
-
Patent Title: Piperazinylpiperidine derivatives as chemokine receptor antagonists Mar. 25, 2014
-
Patent Title: Aza spiro alkane derivatives as inhibitors of metalloproteases Jan. 28, 2014
-
Patent Title: Methods of diagnosing pancreatic inflammation by using chemokine panec-1 antibodies Dec. 31, 2013
-
Patent Title: 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors Dec. 10, 2013
-
Patent Title: Secreted proteins Oct. 29, 2013
-
Patent Title: 3-aminocyclopentanecarboxamides as modulators of chemokine receptors Oct. 22, 2013
-
Patent Title: Lactam compounds and their use as pharmaceuticals Oct. 22, 2013
-
Patent Title: Azepine inhibitors of janus kinases Oct. 22, 2013
-
Patent Title: Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Sep. 24, 2013
-
Patent Title: Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Sep. 10, 2013
-
Patent Title: Substituted heterocycles as janus kinase inhibitors Aug. 20, 2013
-
Patent Title: N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase Aug. 13, 2013
Federal grants, loans, and purchases
- $541,104 2025-04-28 00:00:00 Agency: Department of Veterans Affairs
- $119,619 2024-07-02 00:00:00 Agency: Department of Veterans Affairs
- $541,104 2024-04-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-03-15 00:00:00 Agency: Department of Veterans Affairs
- $13,291 2024-01-26 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2024-01-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-12-12 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-29 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-11-03 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-09-25 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-07-28 00:00:00 Agency: Department of Veterans Affairs
- $12,725 2023-06-13 00:00:00 Agency: Department of Veterans Affairs
- $12,874 2023-05-02 00:00:00 Agency: Department of Veterans Affairs
- $12,812 2023-04-20 00:00:00 Agency: Department of Veterans Affairs
- $675,000 2023-04-11 00:00:00 Agency: Department of Veterans Affairs
- $38,199 2023-03-15 00:00:00 Agency: Department of Veterans Affairs
- $82,626 2022-06-30 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $76,351 2022-04-27 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $499,918 2022-02-18 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2022-02-04 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded to INCY from public contracts
Recent insights relating to INCY
Recent picks made for INCY stock on CNBC
ETFs with the largest estimated holdings in INCY
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $INCY stock a Buy, Sell, or Hold?
- What is the price target for $INCY stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $INCY stock?
- Who owns the most shares of $INCY stock?
- What funds own $INCY stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view INCY Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
- Address Wilmington, DE
- Market Cap 18.4 billion
- Employees 2,844
- Industrial Classification Services-Commercial Physical & Biological Research
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|